Literature DB >> 18226668

Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.

Andrew M Kaunitz1, Raquel Arias, Michael McClung.   

Abstract

BACKGROUND: While depot medroxyprogesterone acetate (DMPA) is a highly effective contraceptive used by millions of women, its use is associated with bone mineral density (BMD) loss, raising concerns about long-term risk of osteoporosis and/or fractures. STUDY
DESIGN: We conducted a systematic review of studies published in PubMed from 1996 to 2006, evaluating changes in BMD after discontinuation of DMPA. Ten primary clinical or observational studies were identified addressing this issue.
RESULTS: BMD consistently returned toward or to baseline values following DMPA discontinuation in women of all ages. This recovery in BMD was seen as early as 24 weeks after stopping therapy and persisted for as long as women were followed up; BMD in past DMPA users was similar to that in nonusers.
CONCLUSIONS: Bone loss occurring with DMPA use is reversible and is not likely to be an important risk factor for low bone density and fractures in older women, although data on fracture risk in DMPA users are lacking.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226668     DOI: 10.1016/j.contraception.2007.10.005

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  19 in total

1.  Depot medroxyprogesterone acetate use and periodontal health in 15- to 44-year-old US females.

Authors:  L Susan Taichman; Woosung Sohn; Giselle Kolenic; Maryfran Sowers
Journal:  J Periodontol       Date:  2012-02-06       Impact factor: 6.993

Review 2.  Effects of hypogonadism on bone metabolism in female adolescents and young adults.

Authors:  Madhusmita Misra
Journal:  Nat Rev Endocrinol       Date:  2012-01-24       Impact factor: 43.330

3.  Suggestions for effective contraception in isotretinoin therapy.

Authors:  Antonios I Kanelleas; Steve Thornton; John Berth-Jones
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 4.  Update on medications with adverse skeletal effects.

Authors:  Caroline J Davidge Pitts; Ann E Kearns
Journal:  Mayo Clin Proc       Date:  2011-03-09       Impact factor: 7.616

Review 5.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

Review 6.  Adverse bone effects of medications used to treat non-skeletal disorders.

Authors:  N B Watts
Journal:  Osteoporos Int       Date:  2017-07-27       Impact factor: 4.507

Review 7.  Knowledge insufficient: the management of haemoglobin SC disease.

Authors:  Lydia H Pecker; Beverly A Schaefer; Lori Luchtman-Jones
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

8.  Predictors of higher bone mineral density loss and use of depot medroxyprogesterone acetate.

Authors:  Mahbubur Rahman; Abbey B Berenson
Journal:  Obstet Gynecol       Date:  2010-01       Impact factor: 7.661

9.  Evaluation and management of the premenopausal woman with low BMD.

Authors:  Adi Cohen; Elizabeth Shane
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

10.  Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception.

Authors:  Mags E Beksinska; Immo Kleinschmidt; Jenni A Smit; Timothy M M Farley; Helen V Rees
Journal:  Contraception       Date:  2009-03-19       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.